Natera, Inc. $NTRA Shares Acquired by IFP Advisors Inc

IFP Advisors Inc lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 250.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,336 shares of the medical research company's stock after purchasing an additional 3,812 shares during the period. IFP Advisors Inc's holdings in Natera were worth $1,448,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Trust Co. of Vermont acquired a new position in shares of Natera during the 2nd quarter worth about $26,000. Reflection Asset Management purchased a new position in shares of Natera in the 4th quarter valued at about $29,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera during the 2nd quarter worth about $30,000. Palladiem LLC acquired a new stake in shares of Natera during the 4th quarter worth about $31,000. Finally, Horizon Investments LLC purchased a new stake in Natera during the third quarter worth approximately $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Buying and Selling

In other news, insider John Fesko sold 6,517 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares in the company, valued at $63,424,043.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Rowan E. Chapman sold 2,964 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director directly owned 3,124 shares of the company's stock, valued at approximately $677,220.72. This represents a 48.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,206 shares of company stock worth $19,944,069. 5.05% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NTRA shares. Guggenheim upped their price target on Natera from $290.00 to $360.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Robert W. Baird set a $348.00 price objective on shares of Natera in a report on Friday, August 7th. Leerink Partners set a $330.00 price objective on shares of Natera in a research report on Friday, August 7th. TD Cowen upped their target price on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a report on Friday, August 7th. Finally, Barclays reaffirmed an "overweight" rating and issued a $340.00 target price on shares of Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $330.83.

Natera Stock Performance

NASDAQ NTRA opened at $328.93 on Friday. The firm's fifty day moving average is $297.80 and its two-hundred day moving average is $241.66. Natera, Inc. has a one year low of $157.43 and a one year high of $343.18. The firm has a market cap of $47.41 billion, a PE ratio of -241.86 and a beta of 1.54.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. Research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.